Arbutus Biopharma Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Arbutus Biopharma

ABUS 4.615

+0.5%

Oct 29 3:59 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: donpat	8/27/2014 5:59:16 PM
	of 42

MARKET REPORT: Merger mania in healthcare sector keeps dealers on toes during peak holiday weeks with Tekmira now high on takeover tonic By GEOFF FOSTER FOR THE DAILY MAIL PUBLISHED: 21:03 GMT, 27 August 2014 \| UPDATED: 21:03 GMT, 27 August 2014 Merger mania in the healthcare sector has kept dealers on their toes during the peak holiday weeks. Cash-rich pharmaceutical majors are forever looking to acquire their smaller, more nimble counterparts, and are prepared to pay stonking premium prices. Last weekend, Californian-based InterMune was swallowed by Swiss drugs giant Roche for an eye-watering $8.3bn. The market now hears rumours that at least four international drug groups are stalking a company that is developing an experimental treatment for the deadly ebola virus. Shares of Tekmira Pharmaceuticals rose 3.24 per cent to $19.75 following a sharp increase last week on news that it has verbal approval from the US Food & Drug Administration that would fast-track its new drug to treat the virus. This action may allow the medicine to be used to treat the growing tally of those stricken by the virus. TKM-Ebola is being developed by Tekmira and the US Department of Defence medical team. Tekmira is capitalised at a measly £400m and would cost a bidder in the region of £1bn-plus, a relatively small mouthful for any cash-rich giant. Rumours suggest two of the interested parties could be the UK’s Shire (22p off at 4894p) and GlaxoSmithKline (15.5p dearer at 1463p. The mega premium paid for InterMune puts a valuation of $40 plus a-share on Tekmira. The outbreak of ebola in Africa has killed more than 1,000 people since February and is the worst since the disease was discovered in the mid-1970s dailymail.co.uk

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next